Tools
Stock profile

HAEMONETICS CORP (HAE)

HAE · Latest close $122.86 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$122.86
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

HAEMONETICS CORP (HAE) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $101.1K sold). Latest close $122.86 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 11, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-101.1K
Fundamentals
Revenue · FY2026
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Ariel Investments · Aequim Alternative Investments — 2 tracked funds hold HAE. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($101.1K). Insider trading

Often held alongside

BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Ariel Investments1.54%2,060,966NEW Q3 filed Nov 13
Aequim Alternative Investments0.06%51,200HELD Q3 filed Nov 12

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +61.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

127.4244.482024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding329 of 8,857 filers
Long-only filers among them327
Change vs 2026 Q1+14 net · 316 entered · 302 exited
Shares reported, all filers49,596,049
Reported value, all filers$3.6B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2026$1.3B
Net income · FY2026$97.3M
Total assets · FY2026$2.4B
Shares outstanding45,497,051
Market cap (at latest close)$5.6B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20263,428,091
Share of shares outstanding7.53%
Days to cover3.89

Shares short at recent settlements — Jul 31, 2026: 2.9M · Aug 14, 2026: 2.8M · Aug 31, 2026: 2.9M · Sep 15, 2026: 3.4M · Sep 30, 2026: 3.0M · Oct 15, 2026: 3.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($101.1K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 11, 2026Maunsell Farris MaryanneVP, Chief Accounting OfficerSell836$120.99$101.1KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jun 26, 2025Llorens JosepFormer Officer18,630$1.4MJun 26, 2025SEC filing
Jun 12, 2025Strong Stewart WFormer Officer708$50.6KJun 12, 2025SEC filing
Jun 4, 2025Strong Stewart WOfficer7,705$538.6KJun 4, 2025SEC filing
Jun 2, 2025Strong Stewart WOfficer2,835$191.3KJun 2, 2025SEC filing
May 19, 2025Llorens JosepOfficer1,547$107.3KMay 19, 2025SEC filing
Nov 12, 2024Lingamneni AnilaFormer Officer6,238$565.7KNov 11, 2024SEC filing
Jul 26, 2024Strong Stewart WOfficer4,312$393.0KJul 26, 2024SEC filing
Jul 12, 2024Lingamneni AnilaOfficer79$7.1KJul 12, 2024SEC filing
Jul 11, 2024Lingamneni AnilaOfficer2,136$192.2KJul 11, 2024SEC filing
May 29, 2024Basil Michelle LOfficer12,990$1.1MMay 29, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 12, 2026AQR Capital Management, LLCSC 13G/A2,266,4895.0%Jun 30, 2026SEC filing
May 13, 2026North Peak Capital Management, LLCSC 13G/A00.0%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G2,445,8175.3%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G2,600,1455.6%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Mar 3, 2026North Peak Capital Management, LLCSC 13G2,370,4955.1%Feb 24, 2026SEC filing
Feb 13, 2026AQR Capital Management, LLCSC 13G3,163,1046.8%Dec 31, 2025SEC filing
Aug 12, 2025Wellington Management Group LLPSC 13G/A2,203,3514.6%Jun 30, 2025SEC filing
May 14, 2025T. Rowe Price Investment Management, Inc.SC 13G/A2,195,5694.4%Mar 31, 2025SEC filing
May 12, 2025Wellington Management Group LLPSC 13G/A2,688,4865.4%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 10 Lobbying Disclosure Act filings named this company as client, 2012–2014; most common issues: Health Issues (9).

Federal contracts: $2.2M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$158.7K
FY2022$261.2K
FY2023$684.1K
FY2024$195.3K
FY2025$398.2K
FY2026$488.2K

Largest awards collected

Award IDAgencyAmountStart
HT001113F0054Department of Defense$17.1MSep 30, 2013
36C10G23K0015Department of Veterans Affairs$176.4KApr 30, 2021
W81K0018P0533Department of Defense$150.4KOct 1, 2018
80NSSC26P0484National Aeronautics and Space Administration$131.9KJul 1, 2026
36C10G24K0029Department of Veterans Affairs$125.6KFeb 28, 2022

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Graham — Sound finances and a long run of profits

· Piotroski — Financial health improved over the past year

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Graham — Current ratio: 2.95 · Straight profitable years: 9 · Debt ratio: — · Latest net income: $97.3M

· Piotroski — F-score: 7 · Return on assets: 4.1% · Operating cash flow: $293.2M

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.88 · Operating cash flow: $293.2M · Net income: $97.3M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold HAE — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 8, 20267.01 Regulation FD DisclosureSEC filing
Aug 18, 20267.01 Regulation FD DisclosureSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on HAE

One email a week: the week’s new filings and research. Subscribe free

← H  ·  HAFN →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.